Government beneficiaries are excluded
Regulated as a cosmetic, meaning manufacturers cannot claim it cures or prevents disease
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M , Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ
novonordisk.com/content/nncorp Top-Line Summary: REDEFINE 4 (CagriSema vs Tirzepatide) - - - CagriSema: 23.0% weight loss (efficacy estimand) Tirzepatide: 25.5% weight loss Treatment-regimen estimand: CagriSema 20.2% Tirzepatide 23.6% Primary endpoint: Not met (non-inferiority) Safety: Mostly GI AEs, consistent with class Perspective: A therapy producing ~23% weight loss is framed as missing. Thats how far obesity pharmacotherapy has progressed
Kietzman D, Bock KW, Krahmer B, Kettler D, Bircher J: Paracetamol test: modification by renal function, urine flow, and pH
Shotsy, Regimen, and Pep AI are trademarks of their respective owners